Comparison of Hospital Readmission for Carotid Interventions  by Hupp, Colleen S. et al.
Abstracts from the 2012 Midwestern Vascular Surgical Society
Annual Meeting
Comparison of Hospital Readmission for Carotid Interventions
Colleen S. Hupp, Robin L. Kruse, PhD, W. Kirt Nichols, MD, Viktor Y.
Dombrovskiy, PhD, and Todd R. Vogel, MD. University of Missouri
Hospitals and Clinics, Columbia, MO; and UMDNJ, New Brunswick, NJ
Objective: Interventions for carotid artery disease are typically well
tolerated and involve an overnight admission. Few studies have evaluated
rates of readmission in the Medicare population comparing less invasive
carotid artery stenting (CAS) with traditional open carotid endarterectomy
(CEA). The objective of this study was to evaluate readmission rates after
CEA and CAS and identify predictors of readmission.
Methods: MedPAR data (2005-2009) were used to select patients
who underwent CEA or CAS according to International Classification of
Diseases-9th Edition-Clinical Modification codes. Readmission within 30,
60, and 90 days from time of procedure was determined. Sociodemographic
characteristics and Elixhauser comorbidity measures were used to adjust for
confounding. Patients who received CEA and CAS were compared with 2
and multivariable logistic regression analysis.
Results: A total of 235,247 carotid interventions were performed
(211,118 CEA and 24,129 CAS). Readmission rates for CEA and CAS
patients, respectively, were 8.84% and 11.11% at 30 days (P  .0001),
13.31% and 17.98% at 60 days (P  .0001) and 16.86% and 22.68% at 90
days (P  .0001). Less than half of patients were women (43%) and were
more likely to be readmitted during 30 days after discharge (P .001). After
adjustment for age, race, gender, comorbidities, and procedure, patients
aged 80 years (odds ratio [OR], 1.25; 95% confidence interval [CI],
1.20-1.30) and patients with renal failure (OR, 1.6; 95% CI, 1.56-1.73),
congestive heart failure (OR, 1.6; 95% CI, 1.57-1.73), or diabetes (OR, 1.4;
95% CI, 1.27-1.52) were more likely to be readmitted. In addition, patients
who underwent CAS were 1.2 times as likely to be readmitted (95% CI,
1.15-1.25) as patients who received CEA. Diagnoses at readmission were
similar between groups.
Conclusions: Interventions for carotid artery disease had a high overall
readmission rate. After adjustment for comorbidities, use of less invasive
techniques (CAS) was not associated with decreased readmission. Patients
who underwent CAS were more likely to be readmitted than those who
received CEA at 30, 60 and 90 days. Predictors of readmission included
advanced age, congestive heart failure, renal failure, and diabetes. Further
research is needed to determine strategies to reduce hospital readmission
rates after carotid interventions.
Contemporary Outcomes After Distal Vertebral Reconstruction
Dawn M. Coleman, MD, Andrea Obi, MD, Enrique Criado, MD, Shipra
Arya, MD, and Ramon Berguer, MD, PhD. Department of Surgery,
Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich
Objectives: Flow-limiting lesions or embolic phenomena can both
produce vertebrobasilar ischemia. This study aims to differentiate the patho-
physiology of vertebral ischemia and examine contemporary outcomes of
distal vertebral reconstruction.
Methods: Thirty-seven consecutive distal vertebral artery (VA) recon-
structions were performed in 34 patients between February 2005 and
November 2011, including bypass to the third portion of the VA (V3) at the
C1-2 level (n  24) or the C0-1 level (n  4); transposition of the external
carotid artery or its occipital branch onto V3 (n  6); transposition of V3
onto the internal carotid artery (n  3); and bypass from the ipsilateral
subclavian artery to V3 (n 1). Five patients required a concomitant carotid
intervention, and three patients required a partial resection of the C1
transverse process. Symptoms, present in 94% of patients, were attributed to
a flow-limiting lesion in 75% (n 24) and to embolization in the remaining
25% (n  8).
Results: Intraoperatively, five patients required graft revision or con-
version of a transposition to a bypass and two patients required vertebral
ligation. Median blood loss was 238 mL. Hospital length of stay averaged 2
days. Postoperatively, one patient required re-exploration for bleeding
(2.7%), and one patient suffered stroke (2.7%). Two patients had cranial
nerve injury (5.4%). There was no perioperative mortality. After a mean
follow-up of 28 months, 91% of patients experienced symptom improve-
ment. Of the 28 patients who underwent follow-up imaging, cumulative
primary patency was 83%, cumulative primary-assisted patency was 93%, and
cumulative secondary patency was 97% (Fig). There were two late deaths of
unknown etiology and no late strokes identified.
Conclusions: Distal VA reconstruction for flow-limiting or embolic
lesions provides excellent long-term patency and stroke protection.
Functional Analysis of Mesenchymal Stem Cells in Ischemic
Conditions
Victor C. Njoku, MD, Reza Saadatzadeh, PhD, Andrea L. Jester, MD, and
Michael P. Murphy, MD. Department of Surgery, Indiana University
School of Medicine, Indianapolis, Ind
Objectives: Mesenchymal stem cells (MSCs) are currently used clini-
cally in cell-based therapies to treat critical limb ischemia via intramuscular
injection, an environment characterized by hypoxia, elevated levels of oxi-
dative stress, and inflammation. In this investigation we compared MSCs
from various tissue sources to assess sensitivity in various in vitro assays that
may predict potency in vivo.
Methods:MSCs from adult bone marrow (BM-MSCs), adipose tissue
(ASCs), and term placenta (P-MSCs) were isolated and characterized using
culture assays and flow cytometry. MSCs were exposed to hydrogen perox-
ide (H2O2), tumor necrosis factor- (TNF-), and hypoxic conditions (1%
oxygen). MSCs were analyzed based on the rate of apoptosis, senescence,
overall survival, and vascular network formation. Apoptosis was measured by
annexin V expression via flow cytometry. Expression of -galactosidase was
detected by light microscopy to quantify senescence. Overall survival was
measured via spectrophotometer detection of methylene blue staining.
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